| glenzocimab (ACT 017) / Acticor Biotech |
2021-002148-56: ADAPTIVE EFFICACY AND SAFETY STUDY OF GLENZOCIMAB USED AS AN ADD-ON THERAPY ON TOP OF STANDARD OF CARE IN THE 4.5 HOURS FOLLOWING AN ACUTE ISCHEMIC STROKE |
|
|
| Not yet recruiting | 2/3 | 1000 | Europe, RoW | glenzocimab, ACT017, Solution for infusion | ACTICOR BIOTECH, ACTICOR BIOTECH | Acute ischemic stroke, Ischemic Stroke is defined as an acute neurologic deficit caused byvascular occlusion or stenosis, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
GALICE, NCT06437431: Glenzocimab in Anterior Stroke With Large Ischemic Core Eligible for Endovascular Therapy |
|
|
| Not yet recruiting | 2/3 | 304 | NA | glenzocimab, placebo | Fondation Ophtalmologique Adolphe de Rothschild | Acute Ischemic Stroke | 10/28 | 10/28 | | |
ACTISAVE, NCT05070260: ACuTe Ischemic Stroke Study Evaluating Glenzocimab Used as Add-on Therapy Versus placEbo |
|
|
| Completed | 2/3 | 438 | Europe, US | Intravenous glenzocimab (ACT017) 1000 mg, Thrombolysis +/- thrombectomy, Intravenous Placebo | Acticor Biotech | Acute Ischemic Stroke | 04/24 | 04/24 | | |
GREEN, NCT05559398: Glenzocimab for REperfusion in the Setting of Endovascular Therapy for Brain infarctioN: Study |
|
|
| Not yet recruiting | 2/3 | 260 | NA | Glenzocimab, Placebo | Assistance Publique - Hôpitaux de Paris | Stroke, Acute, Stroke, Ischemic | 10/25 | 10/26 | | |
2020-002733-15: EXPLORATORY EFFICACY AND SAFETY STUDY OF GLENZOCIMAB IN SARS-Cov-2-RELATED ACUTE RESPIRATORY DISTRESS SYNDROME ÉTUDE ÉVALUANT L’EFFICACITÉ ET LA TOLÉRANCE DE GLENZOCIMAB CHEZ DES PATIENTS SOUFFRANT D’UN SYNDRÔME DE DÉTRESSE RESPIRATOIRE AIGUË DÛ AU VIRUS SARS-Cov-2 |
|
|
| Not yet recruiting | 2 | 40 | Europe | glenzocimab, ACT017, Solution for infusion | ACTICOR BIOTECH, ACTICOR BIOTECH | Respiratory Distress Syndrome Related to SARS-Cov-2 Syndrome de détresse respiratoire lié au SARS-Cov-2, Respiratory Distress Syndrome Related to SARS-Cov-2 Syndrome de détresse respiratoire lié au SARS-Cov-2, Diseases [C] - Virus Diseases [C02] | | | | |
